Issues
-
Cover Image
Cover Image
KIT receptor signaling in mast cells is linked to the recruitment of these immune cells to a variety of solid tumors that express Stem cell factor (SCF). Within tumors, mast cell-derived mediators can enhance growth of the tumor vasculature and promote metastasis. Thus, inhibitors of KIT receptor, or downstream signaling pathways linked to mast cell chemotaxis, may be useful to limit tumor progression. Using a time lapse chemotaxis assay, FES kinase-deficient mast cells (red) were found to migrate less than control mast cells (green) under an agarose drop containing SCF. Interestingly, in FES-deficient mice, mammary tumors expressing SCF also failed to attract comparable mast cells to wild-type control mice, and tumor progression was suppressed. For details, see article by Kwok and colleagues on page 881. - PDF Icon PDF LinkTable of Contents
Molecular Cancer Research
Table of Contents
Highlights
Review
State of the Science: An Update on Renal Cell Carcinoma
Angiogenesis, Metastasis, and the Cellular Microenvironment
Cancer Genes and Genomics
Cell Cycle, Cell Death, and Senescence
A Novel 19q13 Nucleolar Zinc Finger Protein Suppresses Tumor Cell Growth through Inhibiting Ribosome Biogenesis and Inducing Apoptosis but Is Frequently Silenced in Multiple Carcinomas
DNA Damage and Cellular Stress Responses
Akt Promotes Post-Irradiation Survival of Human Tumor Cells through Initiation, Progression, and Termination of DNA-PKcs–Dependent DNA Double-Strand Break Repair
Signaling and Regulation
Cdc42 and the Guanine Nucleotide Exchange Factors Ect2 and Trio Mediate Fn14-Induced Migration and Invasion of Glioblastoma Cells
Human ESC Self-renewal Promoting microRNAs Induce Epithelial–Mesenchymal Transition in Hepatocytes by Controlling the PTEN and TGFβ Tumor Suppressor Signaling Pathways
Journal Archive
Molecular Cancer Research
(2002-Present; volumes 1-current)Published monthly since November, 2002.
(ISSN 0008-5472)
Cell Growth & Differentiation
(1990-2002; volumes 1-13)Published monthly 1990- September, 2002.
(ISSN 1044-9523)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.